1
|
Ledneczki I, Némethy Z, Molnár KD, Tapolcsányi P, Ilkei V, Vágó I, Kolok S, Thán M, Laszy J, Balázs O, Krámos B, Szigetvári Á, Bata I, Makó A, Visegrády A, Fodor L, Vastag M, Lévay G, Lendvai B, Greiner I, Éles J. Optimization of Novel α7 Nicotinic Acetylcholine Receptor Positive Allosteric Modulators and the Discovery of a Preclinical Development Candidate Molecule (RGH-560). J Med Chem 2023; 66:16276-16302. [PMID: 37989278 DOI: 10.1021/acs.jmedchem.3c01635] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2023]
Abstract
During optimization of a previously identified lead compound, attempts were made to optimize the reactive indole structural element, the suboptimal metabolic stability, as well as the low kinetic solubility. It was concluded that the indole was important for in vitro activity. With the aim of further improvements, more thorough modifications were also carried out. As a result, a new chemotype (the azetidinespirochromone family) was identified, which proved to be 1 order of magnitude less lipophilic retaining the same high level of in vitro potency as the lead series itself, however, with improved metabolic stability and kinetic solubility. Compound 53 showed the most balanced physicochemical and pharmacological profile with significant in vivo efficacy in the scopolamine-induced amnesia test. Based on these promising results, cognitive enhancement through the positive modulation of α7 nAChRs appears to be a viable approach. Compound 53 was selected to be a preclinical development candidate (as RGH-560).
Collapse
Affiliation(s)
| | - Zsolt Némethy
- Gedeon Richter Plc, 19-21 Gyömői útca, Budapest H-1103, Hungary
| | | | - Pál Tapolcsányi
- Gedeon Richter Plc, 19-21 Gyömői útca, Budapest H-1103, Hungary
| | - Viktor Ilkei
- Gedeon Richter Plc, 19-21 Gyömői útca, Budapest H-1103, Hungary
| | - István Vágó
- Gedeon Richter Plc, 19-21 Gyömői útca, Budapest H-1103, Hungary
| | - Sándor Kolok
- Gedeon Richter Plc, 19-21 Gyömői útca, Budapest H-1103, Hungary
| | - Márta Thán
- Gedeon Richter Plc, 19-21 Gyömői útca, Budapest H-1103, Hungary
| | - Judit Laszy
- Gedeon Richter Plc, 19-21 Gyömői útca, Budapest H-1103, Hungary
| | - Ottilia Balázs
- Gedeon Richter Plc, 19-21 Gyömői útca, Budapest H-1103, Hungary
| | - Balázs Krámos
- Gedeon Richter Plc, 19-21 Gyömői útca, Budapest H-1103, Hungary
| | - Áron Szigetvári
- Gedeon Richter Plc, 19-21 Gyömői útca, Budapest H-1103, Hungary
| | - Imre Bata
- Gedeon Richter Plc, 19-21 Gyömői útca, Budapest H-1103, Hungary
| | - Attila Makó
- Gedeon Richter Plc, 19-21 Gyömői útca, Budapest H-1103, Hungary
| | | | - László Fodor
- Gedeon Richter Plc, 19-21 Gyömői útca, Budapest H-1103, Hungary
| | - Mónika Vastag
- Gedeon Richter Plc, 19-21 Gyömői útca, Budapest H-1103, Hungary
| | - György Lévay
- Gedeon Richter Plc, 19-21 Gyömői útca, Budapest H-1103, Hungary
| | - Balázs Lendvai
- Gedeon Richter Plc, 19-21 Gyömői útca, Budapest H-1103, Hungary
| | - István Greiner
- Gedeon Richter Plc, 19-21 Gyömői útca, Budapest H-1103, Hungary
| | - János Éles
- Gedeon Richter Plc, 19-21 Gyömői útca, Budapest H-1103, Hungary
| |
Collapse
|
2
|
Sanders VR, Millar NS. Potentiation and allosteric agonist activation of α7 nicotinic acetylcholine receptors: binding sites and hypotheses. Pharmacol Res 2023; 191:106759. [PMID: 37023990 DOI: 10.1016/j.phrs.2023.106759] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/06/2023] [Revised: 03/27/2023] [Accepted: 03/30/2023] [Indexed: 04/07/2023]
Abstract
Considerable progress has been made in recent years towards the identification and characterisation of novel subtype-selective modulators of nicotinic acetylcholine receptors (nAChRs). In particular, this has focussed on modulators of α7 nAChRs, a nAChR subtype that has been identified as a target for drug discovery in connection with a range of potential therapeutic applications. This review focusses upon α7-selective modulators that bind to receptor sites other than the extracellular 'orthosteric' agonist binding site for the endogenous agonist acetylcholine (ACh). Such compounds include those that are able to potentiate responses evoked by orthosteric agonists such as ACh (positive allosteric modulators; PAMs) and those that are able to activate α7 nAChRs by direct allosteric activation in the absence of an orthosteric agonist (allosteric agonists or 'ago-PAMs'). There has been considerable debate about the mechanism of action of α7-selective PAMs and allosteric agonists, much of which has centred around identifying the location of their binding sites on α7 nAChRs. Based on a variety of experimental evidence, including recent structural data, there is now clear evidence indicating that at least some α7-selective PAMs bind to an inter-subunit site located in the transmembrane domain. In contrast, there are differing hypotheses about the site or sites at which allosteric agonists bind to α7 nAChRs. It will be argued that the available evidence supports the conclusion that direct allosteric activation by allosteric agonists/ago-PAMs occurs via the same inter-subunit transmembrane site that has been identified for several α7-selective PAMs.
Collapse
Affiliation(s)
- Victoria R Sanders
- Division of Biosciences, University College London, London WC1E 6BT, United Kingdom
| | - Neil S Millar
- Division of Biosciences, University College London, London WC1E 6BT, United Kingdom.
| |
Collapse
|
3
|
Recent Advances in the Discovery of Nicotinic Acetylcholine Receptor Allosteric Modulators. Molecules 2023; 28:molecules28031270. [PMID: 36770942 PMCID: PMC9920195 DOI: 10.3390/molecules28031270] [Citation(s) in RCA: 8] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2022] [Revised: 01/18/2023] [Accepted: 01/26/2023] [Indexed: 01/31/2023] Open
Abstract
Positive allosteric modulators (PAMs), negative allosteric modulators (NAMs), silent agonists, allosteric activating PAMs and neutral or silent allosteric modulators are compounds capable of modulating the nicotinic receptor by interacting at allosteric modulatory sites distinct from the orthosteric sites. This survey is focused on the compounds that have been shown or have been designed to interact with nicotinic receptors as allosteric modulators of different subtypes, mainly α7 and α4β2. Minimal chemical changes can cause a different pharmacological profile, which can then lead to the design of selective modulators. Experimental evidence supports the use of allosteric modulators as therapeutic tools for neurological and non-neurological conditions.
Collapse
|
4
|
Stokes C, Camacho-Hernandez GA, Thakur GA, Wu X, Taylor P, Papke RL. Differential Activation and Desensitization States Promoted by Noncanonical α7 Nicotinic Acetylcholine Receptor Agonists. J Pharmacol Exp Ther 2022; 383:157-171. [PMID: 36279397 PMCID: PMC9553115 DOI: 10.1124/jpet.122.001354] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/14/2022] [Accepted: 08/11/2022] [Indexed: 01/07/2023] Open
Abstract
A series of dipicolyl amine pyrimidines (DPPs) were previously identified as potential α7 agonists by means of a calcium influx assay in the presence of the positive allosteric modulator (PAM) 1-(5-chloro-2,4-dimethoxy-phenyl)-3-(5-methyl-isoxazol-3-yl)-urea (PNU-120596). The compounds lack the quaternary or strongly basic nitrogens of typical nicotinic agonists. Although differing in structure from typical nicotinic agonists, based on crystallographic data with the acetylcholine binding protein, they appeared to engage the site shared by such typical orthosteric agonists. Using oocytes expressing human α7 receptors, we found that the DPPs were efficacious activators of the receptor, with currents showing rapid desensitization characteristic of α7 receptors. However, we note that the rate of recovery from this desensitization depends strongly on structural features within the DPP family. Although the activation of receptors by DPP was blocked by the competitive antagonist methyllycaconitine (MLA), MLA had no effect on the DPP-induced desensitization, suggesting multiple modes of DPP binding. As expected, the desensitized conformational states could be reactivated by PAMs. Mutants made insensitive to acetylcholine by the C190A mutation in the agonist binding site were weakly activated by DPPs. The observation that activation of C190A mutants by the DPP compounds was resistant to the allosteric antagonist (-)cis-trans-4-(2,3,5,6-tetramethylphenyl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinoline-8-sulfonamide supports the hypothesis that the activity of these noncanonical agonists in the orthosteric binding sites was not entirely dependent on the classic epitopes controlling activation by typical agonists and that perhaps they may access alternative modes for promoting the conformational changes associated with activation and desensitization. SIGNIFICANCE STATEMENT: This study reports a family of nicotinic acetylcholine receptor agonists that break the rules about what the structure of a nicotinic acetylcholine receptor agonist should be. It shows that the activity of these noncanonical agonists in the orthosteric binding sites is not dependent on the classical epitopes controlling activation by typical agonists and that through different binding poses, they promote unique conformational changes associated with receptor activation and desensitization.
Collapse
Affiliation(s)
- Clare Stokes
- Department of Pharmacology, Skaggs School of Pharmacy & Pharmaceutical Sciences, University of California-San Diego, La Jolla, California (G.A.C.-H., X.W., P.T.); Department of Pharmacology and Therapeutics, University of Florida, Gainesville, Florida (C.S., R.L.P.); and Department of Pharmaceutical Sciences, School of Pharmacy, Bouvé College of Health Sciences, Northeastern University, Boston, Massachusetts (G.A.T.)
| | - Gisela Andrea Camacho-Hernandez
- Department of Pharmacology, Skaggs School of Pharmacy & Pharmaceutical Sciences, University of California-San Diego, La Jolla, California (G.A.C.-H., X.W., P.T.); Department of Pharmacology and Therapeutics, University of Florida, Gainesville, Florida (C.S., R.L.P.); and Department of Pharmaceutical Sciences, School of Pharmacy, Bouvé College of Health Sciences, Northeastern University, Boston, Massachusetts (G.A.T.)
| | - Ganesh A Thakur
- Department of Pharmacology, Skaggs School of Pharmacy & Pharmaceutical Sciences, University of California-San Diego, La Jolla, California (G.A.C.-H., X.W., P.T.); Department of Pharmacology and Therapeutics, University of Florida, Gainesville, Florida (C.S., R.L.P.); and Department of Pharmaceutical Sciences, School of Pharmacy, Bouvé College of Health Sciences, Northeastern University, Boston, Massachusetts (G.A.T.)
| | - Xiaoxuan Wu
- Department of Pharmacology, Skaggs School of Pharmacy & Pharmaceutical Sciences, University of California-San Diego, La Jolla, California (G.A.C.-H., X.W., P.T.); Department of Pharmacology and Therapeutics, University of Florida, Gainesville, Florida (C.S., R.L.P.); and Department of Pharmaceutical Sciences, School of Pharmacy, Bouvé College of Health Sciences, Northeastern University, Boston, Massachusetts (G.A.T.)
| | - Palmer Taylor
- Department of Pharmacology, Skaggs School of Pharmacy & Pharmaceutical Sciences, University of California-San Diego, La Jolla, California (G.A.C.-H., X.W., P.T.); Department of Pharmacology and Therapeutics, University of Florida, Gainesville, Florida (C.S., R.L.P.); and Department of Pharmaceutical Sciences, School of Pharmacy, Bouvé College of Health Sciences, Northeastern University, Boston, Massachusetts (G.A.T.)
| | - Roger L Papke
- Department of Pharmacology, Skaggs School of Pharmacy & Pharmaceutical Sciences, University of California-San Diego, La Jolla, California (G.A.C.-H., X.W., P.T.); Department of Pharmacology and Therapeutics, University of Florida, Gainesville, Florida (C.S., R.L.P.); and Department of Pharmaceutical Sciences, School of Pharmacy, Bouvé College of Health Sciences, Northeastern University, Boston, Massachusetts (G.A.T.)
| |
Collapse
|
5
|
Zhu X, Zhou Y, Yuan G, Shi J, Shi S, Zhang L, Chai R, Du Y, Duan C, Hu Y. Bibliometric analysis of nicotinic acetylcholine receptors channel research (2000-2020). Channels (Austin) 2021; 15:298-309. [PMID: 33615989 PMCID: PMC7901545 DOI: 10.1080/19336950.2021.1882113] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/09/2021] [Revised: 01/20/2021] [Accepted: 01/20/2021] [Indexed: 11/15/2022] Open
Abstract
To explore the research status, hotspots, and trends in research on nicotinic acetylcholine receptor (nAChR) channel. The Web of Science core collection database from 2000 to 2020 was used as the data source. The visual analysis software VOSviewer1.6.16 and Citespace5.7 R3 were used to visualize the studies of the nAChR channel. The national/institutional distribution, journal distribution, authors, and related research were discussed. A total of 5,794 articles were obtained. The USA and the Utah System of Higher Education were the most productive country and institution for nAChR channel research. Journal of Biological Chemistry was the most productive journal (212) and the most productive researcher was McIntosh, J. Michael. The first highly co-cited article was "Refined structure of the nicotinic acetylcholine receptor at 4A resolution." The most researched area was neurosciences neurology. The hot spots of nAChR channel research were "subunit and structure of nAChR," "activation/agonist of nAChR channel," and "Changes in nAChRs With Alzheimer's Disease." The top three research frontiers of nAChR channel research were "neuropathic pain," "neuroinflammation," and "α7 nACHR." The study provides a perspective to visualize and analyze hotspots and emerging trends in the nAChR channel.
Collapse
Affiliation(s)
- Xueping Zhu
- Cardiovascular Department, Guanganmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China
| | - Yan Zhou
- Cardiovascular Department, Graduate School of Beijing University of Chinese Medicine, Beijing, China
| | - Guozhen Yuan
- Cardiovascular Department, Guanganmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China
| | - Jingjing Shi
- Cardiovascular Department, Guanganmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China
| | - Shuai Shi
- Cardiovascular Department, Guanganmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China
| | - Limei Zhang
- Cardiovascular Department, Guanganmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China
| | - Ruoning Chai
- Cardiovascular Department, Guanganmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China
| | - Yihang Du
- Cardiovascular Department, Guanganmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China
| | - Chenglin Duan
- Cardiovascular Department, Graduate School of Beijing University of Chinese Medicine, Beijing, China
| | - Yuanhui Hu
- Cardiovascular Department, Guanganmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China
| |
Collapse
|
6
|
Gulsevin A, Papke RL, Stokes C, Tran HNT, Jin AH, Vetter I, Meiler J. The Allosteric Activation of α7 nAChR by α-Conotoxin MrIC Is Modified by Mutations at the Vestibular Site. Toxins (Basel) 2021; 13:toxins13080555. [PMID: 34437426 PMCID: PMC8402416 DOI: 10.3390/toxins13080555] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/28/2021] [Revised: 08/02/2021] [Accepted: 08/09/2021] [Indexed: 12/18/2022] Open
Abstract
α-conotoxins are 13–19 amino acid toxin peptides that bind various nicotinic acetylcholine receptor (nAChR) subtypes. α-conotoxin Mr1.7c (MrIC) is a 17 amino acid peptide that targets α7 nAChR. Although MrIC has no activating effect on α7 nAChR when applied by itself, it evokes a large response when co-applied with the type II positive allosteric modulator PNU-120596, which potentiates the α7 nAChR response by recovering it from a desensitized state. A lack of standalone activity, despite activation upon co-application with a positive allosteric modulator, was previously observed for molecules that bind to an extracellular domain allosteric activation (AA) site at the vestibule of the receptor. We hypothesized that MrIC may activate α7 nAChR allosterically through this site. We ran voltage-clamp electrophysiology experiments and in silico peptide docking calculations in order to gather evidence in support of α7 nAChR activation by MrIC through the AA site. The experiments with the wild-type α7 nAChR supported an allosteric mode of action, which was confirmed by the significantly increased MrIC + PNU-120596 responses of three α7 nAChR AA site mutants that were designed in silico to improve MrIC binding. Overall, our results shed light on the allosteric activation of α7 nAChR by MrIC and suggest the involvement of the AA site.
Collapse
Affiliation(s)
- Alican Gulsevin
- Center for Structural Biology, Department of Chemistry, Vanderbilt University, Nashville, TN 37212, USA;
- Correspondence:
| | - Roger L. Papke
- Department of Pharmacology and Therapeutics, College of Medicine, University of Florida, Gainesville, FL 32610, USA; (R.L.P.); (C.S.)
| | - Clare Stokes
- Department of Pharmacology and Therapeutics, College of Medicine, University of Florida, Gainesville, FL 32610, USA; (R.L.P.); (C.S.)
| | - Hue N. T. Tran
- Institute for Molecular Bioscience, The University of Queensland, St Lucia, QLD 4072, Australia; (H.N.T.T.); (A.H.J.); (I.V.)
| | - Aihua H. Jin
- Institute for Molecular Bioscience, The University of Queensland, St Lucia, QLD 4072, Australia; (H.N.T.T.); (A.H.J.); (I.V.)
| | - Irina Vetter
- Institute for Molecular Bioscience, The University of Queensland, St Lucia, QLD 4072, Australia; (H.N.T.T.); (A.H.J.); (I.V.)
- School of Pharmacy, The University of Queensland, Woolloongabba, QLD 4102, Australia
| | - Jens Meiler
- Center for Structural Biology, Department of Chemistry, Vanderbilt University, Nashville, TN 37212, USA;
- Institute for Drug Discovery, Leipzig University Medical School, 04103 Leipzig, Germany
| |
Collapse
|
7
|
Abstract
The α7-type nicotinic acetylcholine receptor is one of the most unique and interesting of all the members of the cys-loop superfamily of ligand-gated ion channels. Since it was first identified initially as a binding site for α-bungarotoxin in mammalian brain and later as a functional homomeric receptor with relatively high calcium permeability, it has been pursued as a potential therapeutic target for numerous indications, from Alzheimer disease to asthma. In this review, we discuss the history and state of the art for targeting α7 receptors, beginning with subtype-selective agonists and the basic pharmacophore for the selective activation of α7 receptors. A key feature of α7 receptors is their rapid desensitization by standard "orthosteric" agonist, and we discuss insights into the conformational landscape of α7 receptors that has been gained by the development of ligands binding to allosteric sites. Some of these sites are targeted by positive allosteric modulators that have a wide range of effects on the activation profile of the receptors. Other sites are targeted by direct allosteric agonist or antagonists. We include a perspective on the potential importance of α7 receptors for metabotropic as well as ionotropic signaling. We outline the challenges that exist for future development of drugs to target this important receptor and approaches that may be considered to address those challenges. SIGNIFICANCE STATEMENT: The α7-type nicotinic acetylcholine receptor (nAChR) is acknowledged as a potentially important therapeutic target with functional properties associated with both ionotropic and metabotropic signaling. The functional properties of α7 nAChR can be regulated in diverse ways with the variety of orthosteric and allosteric ligands described in this review.
Collapse
Affiliation(s)
- Roger L Papke
- Departments of Pharmacology and Therapeutics (R.L.P) and Chemistry (N.A.H.), University of Florida, Gainesville, FL
| | - Nicole A Horenstein
- Departments of Pharmacology and Therapeutics (R.L.P) and Chemistry (N.A.H.), University of Florida, Gainesville, FL
| |
Collapse
|
8
|
Ledneczki I, Horváth A, Tapolcsányi P, Éles J, Molnár KD, Vágó I, Visegrády A, Kiss L, Szigetvári Á, Kóti J, Krámos B, Mahó S, Holm P, Kolok S, Fodor L, Thán M, Kostyalik D, Balázs O, Vastag M, Greiner I, Lévay G, Lendvai B, Némethy Z. HTS-based discovery and optimization of novel positive allosteric modulators of the α7 nicotinic acetylcholine receptor. Eur J Med Chem 2021; 222:113560. [PMID: 34111828 DOI: 10.1016/j.ejmech.2021.113560] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/26/2021] [Revised: 04/26/2021] [Accepted: 05/18/2021] [Indexed: 12/01/2022]
Abstract
HTS campaign of the corporate compound collection resulted in a novel, oxalic acid diamide scaffold of α7 nACh receptor positive allosteric modulators. During the hit expansion, several derivatives, such as 4, 11, 17 demonstrated not only high in vitro potency, but also in vivo efficacy in the mouse place recognition test. The advanced hit molecule 11 was further optimized by the elimination of the putatively mutagenic aromatic-amine building block that resulted in a novel, aminomethylindole compound family. The most balanced physico-chemical and pharmacological profile was found in case of compound 55. Docking study revealed an intersubunit binding site to be the most probable for our compounds. 55 demonstrated favorable cognitive enhancing profile not only in scopolamine-induced amnesia (place recognition test in mice) but also in natural forgetting (novel object recognition test in rats). Compound 55 was, furthermore, active in a cognitive paradigm of high translational value, namely in the rat touch screen visual discrimination test. Therefore, 55 was selected as a lead compound for further optimization. Based on the obtained favorable results, the invented aminomethylindole cluster may provide a viable approach for cognitive enhancement through positive allosteric modulation of α7 nAChRs.
Collapse
Affiliation(s)
- István Ledneczki
- Department of Chemistry, Gedeon Richter Plc., Budapest, Hungary.
| | - Anita Horváth
- Department of Chemistry, Gedeon Richter Plc., Budapest, Hungary
| | - Pál Tapolcsányi
- Department of Chemistry, Gedeon Richter Plc., Budapest, Hungary
| | - János Éles
- Department of Chemistry, Gedeon Richter Plc., Budapest, Hungary
| | | | - István Vágó
- Department of Chemistry, Gedeon Richter Plc., Budapest, Hungary
| | - András Visegrády
- Pharmacological and Drug Safety Research, Gedeon Richter Plc., Budapest, Hungary
| | - László Kiss
- Pharmacological and Drug Safety Research, Gedeon Richter Plc., Budapest, Hungary
| | - Áron Szigetvári
- Spectroscopic Research Department, Gedeon Richter Plc., Budapest, Hungary
| | - János Kóti
- Spectroscopic Research Department, Gedeon Richter Plc., Budapest, Hungary
| | - Balázs Krámos
- Spectroscopic Research Department, Gedeon Richter Plc., Budapest, Hungary
| | - Sándor Mahó
- Department of Chemistry, Gedeon Richter Plc., Budapest, Hungary
| | | | - Sándor Kolok
- Pharmacological and Drug Safety Research, Gedeon Richter Plc., Budapest, Hungary
| | - László Fodor
- Pharmacological and Drug Safety Research, Gedeon Richter Plc., Budapest, Hungary
| | - Márta Thán
- Pharmacological and Drug Safety Research, Gedeon Richter Plc., Budapest, Hungary
| | - Diána Kostyalik
- Pharmacological and Drug Safety Research, Gedeon Richter Plc., Budapest, Hungary
| | - Ottilia Balázs
- Pharmacological and Drug Safety Research, Gedeon Richter Plc., Budapest, Hungary
| | - Mónika Vastag
- Pharmacological and Drug Safety Research, Gedeon Richter Plc., Budapest, Hungary
| | - István Greiner
- Research Management, Gedeon Richter Plc., Budapest, Hungary
| | - György Lévay
- Pharmacological and Drug Safety Research, Gedeon Richter Plc., Budapest, Hungary
| | - Balázs Lendvai
- Pharmacological and Drug Safety Research, Gedeon Richter Plc., Budapest, Hungary
| | - Zsolt Némethy
- Pharmacological and Drug Safety Research, Gedeon Richter Plc., Budapest, Hungary
| |
Collapse
|
9
|
Pismataro MC, Horenstein NA, Stokes C, Dallanoce C, Thakur GA, Papke RL. Stable desensitization of α 7 nicotinic acetylcholine receptors by NS6740 requires interaction with S36 in the orthosteric agonist binding site. Eur J Pharmacol 2021; 905:174179. [PMID: 34004208 DOI: 10.1016/j.ejphar.2021.174179] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/11/2021] [Revised: 05/05/2021] [Accepted: 05/12/2021] [Indexed: 01/09/2023]
Abstract
NS6740 is an α7 nicotinic acetylcholine receptor-selective partial agonist with low efficacy for channel activation, capable of promoting the stable conversion of the receptors to nonconducting (desensitized) states that can be reactivated with the application of positive allosteric modulators (PAMs). In spite of its low efficacy for channel activation, NS6740 is an effective activator of the cholinergic anti-inflammatory pathway. We observed that the concentration-response relationships for channel activation, both when applied alone and when co-applied with the PAM PNU-120596 are inverted-U shaped with inhibitory/desensitizing activities dominant at high concentrations. We evaluated the potential importance of recently identified binding sites for allosteric activators and tested the hypotheses that the stable desensitization produced by NS6740 may be due to binding to these sites. Our experiments were guided by molecular modeling of NS6740 binding to both the allosteric and orthosteric activation sites on the receptor. Our results indicate that with α7C190A mutants, which have compromised orthosteric activation sites, NS6740 may work at the allosteric activation sites to promote transient PAM-dependent currents but not the stable desensitization seen with wild-type α7 receptors. Modeling NS6740 in the orthosteric binding sites identified S36 as an important residue for NS6740 binding and predicted that an S36V mutation would limit NS6740 activity. The efficacy of NS6740 for α7S36V receptors was reduced to zero, and applications of the compound to α7S36V receptors failed to induce the desensitization observed with wild-type receptors. The results indicate that the unique properties of NS6740 are due primarily to binding at the sites for orthosteric agonists.
Collapse
Affiliation(s)
- Maria Chiara Pismataro
- Department of Pharmaceutical Sciences, Medicinal Chemistry Section "Pietro Pratesi", University of Milan, Via L. Mangiagalli 25, 20133, Milan, Italy; Department of Chemistry, University of Florida, P.O. Box 117200, Gainesville, FL, 32611-7200, USA
| | - Nicole A Horenstein
- Department of Chemistry, University of Florida, P.O. Box 117200, Gainesville, FL, 32611-7200, USA
| | - Clare Stokes
- Department of Pharmacology and Therapeutics, University of Florida, P.O. Box 100267, Gainesville, FL, 32610-0267, USA
| | - Clelia Dallanoce
- Department of Pharmaceutical Sciences, Medicinal Chemistry Section "Pietro Pratesi", University of Milan, Via L. Mangiagalli 25, 20133, Milan, Italy.
| | - Ganesh A Thakur
- Department of Pharmaceutical Sciences, School of Pharmacy, Bouvé College of Health Sciences, Northeastern University, Boston, MA, 02115, USA
| | - Roger L Papke
- Department of Pharmacology and Therapeutics, University of Florida, P.O. Box 100267, Gainesville, FL, 32610-0267, USA
| |
Collapse
|
10
|
Gulsevin A, Meiler J, Horenstein NA. A Computational Analysis of the Factors Governing the Dynamics of α7 nAChR and Its Homologs. Biophys J 2020; 119:1656-1669. [PMID: 33010233 PMCID: PMC7642335 DOI: 10.1016/j.bpj.2020.09.006] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/25/2020] [Revised: 09/10/2020] [Accepted: 09/10/2020] [Indexed: 12/18/2022] Open
Abstract
The α7 nicotinic acetylcholine receptor is a homopentameric ion channel from the Cys-loop receptor superfamily targeted for psychiatric indications and inflammatory pain. Molecular dynamics studies of the receptor have focused on residue mobility and global conformational changes to address receptor function. However, a comparative analysis of α7 with its homologs that cannot trigger channel opening has not been made so far. To identify the residues involved in α7 activation, we ran triplicate 500-ns molecular dynamics simulations with an α7 extracellular domain homology model and two acetylcholine-binding protein homologs. We tested the effect of ligand binding and amino acid sequence on the structure and dynamics of the three proteins. We found that mobile regions identified based on root mean-square deviation and root mean-square fluctuation values are not always consistent among the individual α7 extracellular domain simulations. Comparison of the replica-average properties of the three proteins based on dynamic cross-correlation maps showed that ligand binding affects the coupling between the C-loop and the Cys-loop, vestibular loop, and β1-β2 loops. In addition, the main-immunogenic-region-like domain of α7 went through correlated motions with multiple domains of the receptor. These correlated motions were absent or diminished in α7 homologs, suggesting a unique role in α7 activation.
Collapse
Affiliation(s)
- Alican Gulsevin
- Department of Chemistry, Biochemistry Division, University of Florida, Gainesville, Florida; Department of Chemistry, Vanderbilt University, Nashville, Tennessee.
| | - Jens Meiler
- Department of Chemistry, Vanderbilt University, Nashville, Tennessee; Leipzig University Medical School, Institute for Drug Discovery, Leipzig, Germany
| | - Nicole A Horenstein
- Department of Chemistry, Biochemistry Division, University of Florida, Gainesville, Florida
| |
Collapse
|